sii tetanus antitoxin vaccine 1500
serum institute of india pvt. ltd. (siipl), india - tetanus antitoxin - vaccine - 1500
tetanus antitoxin 1500 iu/ml bp 1500 iu/ml parenteral ordinary vials
biological e. limited - tetanus antitoxin - parenteral ordinary vials - 1500 iu/ml
antistax capsules
sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - vitis vinifera -
antistax film coated tablets
sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - vitis vinifera -
antitox 2 formula a.k.a. huang lian jie du tang
sun herbal pty ltd - gardenia jasminoides, quantity: 85.8 mg (equivalent: gardenia jasminoides, qty 514.8 mg); scutellaria baicalensis, quantity: 85.8 mg (equivalent: scutellaria baicalensis, qty 514.8 mg); phellodendron amurense, quantity: 85.8 mg (equivalent: phellodendron amurense, qty 514.8 mg); coptis chinensis, quantity: 42.6 mg (equivalent: coptis chinensis, qty 255.6 mg) - capsule, hard - excipient ingredients: carrageenan; soluble maize starch; sodium citrate dihydrate; agar; hypromellose - traditionally used in chinese medicine to dispel/expel/disperse/clear fire ; traditionally used in chinese medicine to remove heat toxin
northern serums canine paralysis tick antiserum
northern serums pty ltd - antitoxin; mixed isomers of cresol - misc. vaccines or anti sera - antitoxin miscellaneous active 500.0 units/ml; mixed isomers of cresol phenol other 0.0017 ml/ml - immunotherapy - calf | cat | dog | horse foal | pigs | sheep | beef calf | bitch | boar | bovine | calf - poddy | calf - preweaning | calf - suc - paralysis tick | australian paralysis tick | scrub tick
tetanus antitoxin behring
intervet ireland limited - equine serum protein - solution for injection - unknown - clostridium antiserum qi05am01 clostridium antiserum qi07am antisera, immunoglobulin preparations, and antitoxins - canine, equine - food, ovine - immunological - antiserum
tetanus antitoxin behring
intervet ireland limited - equine serum protein - solution for injection - . - clostridium antiserum; clostridium antiserum; antisera, immunoglobulin preparations, and antitoxins - dogs, horses, sheep - immunological- antiserum
bat- botulism antitoxin heptavalent liquid
emergent biosolutions canada inc. - equine botulinum neurotoxin a immune fab2 (unii: le3j6i6dxp) (equine botulinum neurotoxin a immune fab2 - unii:le3j6i6dxp), equine botulinum neurotoxin b immune fab2 (unii: vsk09vp4hl) (equine botulinum neurotoxin b immune fab2 - unii:vsk09vp4hl), equine botulinum neurotoxin c immune fab2 (unii: x5i2p7e9ty) (equine botulinum neurotoxin c immune fab2 - unii:x5i2p7e9ty), equine botulinum neurotoxin d immune fab2 (unii: 30y9n0sebe) (equine botulinum neurotoxin d immune fab2 - unii:30y9n0sebe), equine botul - equine botulinum neurotoxin a immune fab2 4500 [iu] in 10 ml - bat [botulism antitoxin heptavalent (a, b, c, d, e, f, g) – (equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes a, b, c, d, e, f, or g in adults and pediatric patients. the effectiveness of bat is based on efficacy studies conducted in animal models of botulism. none. risk summary there are no human or animal data to establish the presence or absence of bat associated risk. risk summary there are no data to assess the presence or absence of bat in human milk, the effects on the breastfed child or the effects on milk production/excretion. consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for bat and any potential adverse effects on the breastfed child from bat or from the underlying maternal condition. the effectiveness of bat has not been established in pediatric patients. limited pediatric safety data are available. fifteen pediat
diphtheria antitoxin
wellcome (ireland) limited - diphtheria antitoxin -